G Trams

Learn More
Individually different growth responses of 10 cell lines newly derived from metastasizing mammary carcinomas were determined by cell counts in experimental incubations with the steroid hormones 17 beta-estradiol, progesterone, testosterone, hydrocortisone (cortisol), the antiestrogenic compound tamoxifen, or prolactin. Of 7 cell lines derived from ductal(More)
Estrogen and dihydrotestosterone receptors were detected by agar gel electrophoresis in 224 human mammary tumor biopsies. Approximately half of the tumor specimens revealed measurable amounts of estradiol receptors, whereas only 20% contained dihydrotestosterone receptors. The average concentration of spare estrogetmenopausal than in the premenopausal(More)
Patients with advanced breast cancer and low or poor concentration of estrogen receptors in tumor biopsies have little chance of responding to endocrine therapy. This problem was seen in a group of nonresponding estrogen receptor-positive (ER+) patients. Some comments on possible explanations for this phenomenon are made and suggestions to overcome it are(More)
Specific DNA repeats serve as a molecular protection shield at the telomeric ends of mammalian chromosomes. The absence of telomerase activity leads to a gradual decrease of telomeric repeat length in normal somatic cells. In contrast, immortalized cells from malignant tumors are usually thought to re-express telomerase to overcome a self-limited growth.(More)
We are reporting a rare case of secretory breast cancer with axillary node involvement in a 16-year-old patient. Symptomatic systemic spread occured unusually early during adjuvant chemotherapy, suggesting primary resistance of the tumour to chemotherapy. We are unaware of any such case reports published world wide. Due to the small number of similar case(More)
The results of adjuvant chemotherapy in the treatment of primary cancer of the breast is reported. During 44 months 401 patients were admitted to the prospective study. All patients with a cancer of the breast T1a-3a, N0-1b, M0 were operated by modification of the Patey procedure. N+ patients were treated for one year postoperatively with TMF chemotherapy(More)